calcium bis((3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoate)

• ChemBase ID: 72797
• Molecular Formular: C50H46CaF2N2O8
• Molecular Mass: 880.9836464
• Monoisotopic Mass: 880.28481386
• SMILES: c1ccc2c(c1)c(c(c(n2)C1CC1)/C=C/[C@@H](O)C[C@H](CC(=O)[O-])O)c1ccc(cc1)F.c1(c(c(c2c(n1)cccc2)c1ccc(cc1)F)/C=C/[C@@H](O)C[C@H](CC(=O)[O-])O)C1CC1.[Ca+2]
• Canonical SMILES: O[C@H](C[C@@H](/C=C/c1c(nc2c(c1c1ccc(cc1)F)cccc2)C1CC1)O)CC(=O)[O-].O[C@H](C[C@@H](/C=C/c1c(nc2c(c1c1ccc(cc1)F)cccc2)C1CC1)O)CC(=O)[O-].[Ca+2]
• InChI: InChI=1S/2C25H24FNO4.Ca/c2*26-17-9-7-15(8-10-17)24-20-3-1-2-4-22(20)27-25(16-5-6-16)21(24)12-11-18(28)13-19(29)14-23(30)31;/h2*1-4,7-12,16,18-19,28-29H,5-6,13-14H2,(H,30,31);/q;;+2/p-2/b2*12-11+;/t2*18-,19-;/m11./s1
• InChIKey: RHGYHLPFVJEAOC-FFNUKLMVSA-L

NAMES AND DATABASE IDS

Names

• IUPAC name: calcium bis((3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoate)
• IUPAC Traditional name: calcium(2+) bis((3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoate); calcium bis((3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoate)
• Synonyms: Livalo; Pitavastatin calcium

Database IDs

• CAS Number: 147526-32-7
• PubChem SID: 162037718
• PubChem CID: 5282451

CALCULATED PROPERTIES

• Acid pKa: 4.1270967
• H Acceptors: 5
• H Donor: 2
• LogD (pH = 5.5): 2.5521677
• LogD (pH = 7.4): 0.88797456
• Log P: 2.9240363
• Molar Refractivity: 126.5763 cm^3
• Polarizability: 46.615173 Å^3
• Polar Surface Area: 93.48 Å^2
• Rotatable Bonds: 16
• Lipinski's Rule of Five: false

PROPERTIES

Safety Information

• Storage Condition: -20°C

Product Information

• Purity: 95+%
• Salt Data: Calcium

DETAILS

Selleck Chemicals - S1759

Research Area: Cardiovascular Disease
Biological Activity:
Pitavastatin calcium(Livalo) is a novel member of the medication class of statins. Like the other statins, it is an inhibitor of HMG-CoA reductase, the enzyme that catalyses the first step of cholesterol synthesis. Most statins are metabolised in part by one or more hepatic cytochrome P450 enzymes, leading to an increased potential for drug interactions and problems with certain foods (such as grapefruit juice). Pitavastatin appears to be a substrate of CYP2C9, and not CYP3A4 (which is a common source of interactions in other statins). [1] 

REFERENCES

• http://en.wikipedia.org/wiki/Pitavastatin